[HTML][HTML] Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma

A Engert, A Plütschow, HT Eich, A Lohri… - … England Journal of …, 2010 - Mass Medical Soc
Background Whether it is possible to reduce the intensity of treatment in early (stage I or II)
Hodgkin's lymphoma with a favorable prognosis remains unclear. We therefore conducted a …

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive …

…, R Zschaber, P Müller, H Kirchner, A Lohri… - The Lancet, 2002 - thelancet.com
Background High-dose chemotherapy followed by transplantation of autologous haemopoietic
stem cells (BEAMHSCT) is frequently used to treat patients with relapsed Hodgkin's …

[PDF][PDF] Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study

A Engert, V Diehl, J Franklin, A Lohri… - Journal of Clinical …, 2009 - researchgate.net
Purpose The HD9 trial of the German Hodgkin Study Group compared two different doses (baseline
and escalated) of the bleomycin, etoposide, doxorubicin, cyclophosphamide, …

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard …

…, E Zucca, R Stupp, T Kovacsovics, C Helg, A Lohri… - Blood, 2004 - ashpublications.org
The potential benefits of extended rituximab treatment have been investigated in a randomized
trial comparing the standard schedule with prolonged treatment in 202 patients with …

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the …

P Borchmann, H Goergen, C Kobe, A Lohri, R Greil… - The Lancet, 2017 - thelancet.com
Background The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses…

[PDF][PDF] Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial

…, A Plütschow, M Fuchs, B Klimm, J Markova, A Lohri… - J Clin …, 2012 - medspec.co.za
Purpose In patients with early unfavorable Hodgkin’s lymphoma (HL), combined modality
treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and …

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in …

…, J Franklin, J Markova, A Lohri… - Blood, The Journal …, 2008 - ashpublications.org
In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV)
of positron emission tomography (PET) using [ 18 F]-fluorodeoxyglucose in advanced-stage …

[PDF][PDF] Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

…, M Heizmann, D Vorobiof, A Lohri… - Journal of clinical …, 2010 - researchgate.net
Purpose We report the long-term results of a randomized clinical trial comparing induction
therapy with once per week for 4 weeks single-agent rituximab alone versus induction …

Positron emission tomography–guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the …

…, H Goergen, C Kobe, G Kuhnert, A Lohri… - Journal of clinical …, 2019 - ascopubs.org
PURPOSE Combined-modality treatment (CMT) with 2× ABVD (doxorubicin, bleomycin,
vinblastine, and dacarbazine) and small-field radiotherapy is standard of care for patients with …

Autoimmunity and malignancy in hematology—more than an association

M Stern, AS Buser, A Lohri, A Tichelli… - Critical reviews in …, 2007 - Elsevier
Several associations between hematological malignancies and autoimmunity directed
against hematopoietic cells exist. Antibody mediated elimination of mature blood cells such as …